Tudományos kitekintés – Rheumatológia

Genetic data: The new challenge of personalized medicine, insights for rheumatoid arthritis patients.

Goulielmos GN, Zervou MI, Myrthianou E, Burska A, Niewold TB, Ponchel F. Abstract Rapid advances in genotyping technology, analytical methods, and the establishment of large cohorts for population genetic studies have resulted in a large new body of information about the genetic basis of human rheumatoid arthritis (RA). Improved understanding of the root pathogenesis of(…)

Biologic efficacy optimization-a step towards personalized medicine.

Rheumatology (Oxford). 2015 Sep 30. pii: kev356. [Epub ahead of print] Kiely PD1. Abstract This following is a review of the factors that influence the outcome of biologic agents in the treatment of adult RA and, when synthesized into the clinical decision-making process, enhance optimization. Adiposity can exacerbate inflammatory diseases; patients with high BMI have(…)

Human leukocyte antigen polymorphisms and personalized medicine for rheumatoid arthritis.

J Hum Genet. 2015 Nov;60(11):691-6. doi: 10.1038/jhg.2015.36. Epub 2015 Apr 23. Furukawa H1, Oka S1, Shimada K2,3, Hashimoto A2, Tohma S1. Abstract Human leukocyte antigen (HLA) polymorphisms are the most important genetic risk factors for rheumatoid arthritis (RA), a chronic systemic inflammatory disease of unknown etiology. Certain HLA-DRB1 alleles, known as shared epitope (SE) alleles(…)

Personalized medicine in rheumatoid arthritis: is the glass half full or half empty?

J Intern Med. 2015 Feb;277(2):178-87. doi: 10.1111/joim.12319. Huizinga TW1. Abstract The care of patients with rheumatoid arthritis (RA) has been revolutionized since the 1990s. Strict monitoring and disease control based on measurement of signs and symptoms towards a target of low disease activity have improved outcome of patients enormously. As a result of treatment strategies(…)

Rheumatoid arthritis: a case for personalized health care?

Arthritis Care Res (Hoboken). 2014 Sep;66(9):1273-80. doi: 10.1002/acr.22289. Karsdal MA1, Bay-Jensen AC, Henriksen K, Christiansen C, Genant HK, Chamberlain C, Platt A. PMID: 24470057 [PubMed – indexed for MEDLINE] http://www.ncbi.nlm.nih.gov/pubmed/24470057

High anti-CCP antibody titres predict good response to rituximab in patients with active rheumatoid arthritis.

Gardette A1, Ottaviani S2, Tubach F3, Roy C3, Nicaise-Roland P4, Palazzo E1, Gill G1, Meyer O1, Dieudé P5. Abstract OBJECTIVE: Previous studies reported that anti-CCP antibody positivity predicts good response to rituximab (RTX) in rheumatoid arthritis (RA). A quantitative approach to such possibility could be a good way to detect the subset of patients most(…)

Moving towards personalized medicine in rheumatoid arthritis.

de Jong TD, Vosslamber S, Verweij CL. Abstract To develop personalized medicine strategies for improvement of patient management in rheumatoid arthritis, the clinical and molecular properties of the individual patients need to be well characterized. A crucial step in this approach is to discover subgroups of patients that are characterized by a good or poor(…)

Gene expression analysis in RA: towards personalized medicine.

Burska AN1, Roget K2, Blits M3, Soto Gomez L4, van de Loo F5, Hazelwood LD6, Verweij CL3, Rowe A7,Goulielmos GN8, van Baarsen LG9, Ponchel F1. Author information Abstract Gene expression has recently been at the forefront of advance in personalized medicine, notably in the field of cancer and transplantation, providing a rational for a similar(…)

Osteoarthritis–a case for personalized health care?

Osteoarthritis Cartilage. 2014 Jan;22(1):7-16. doi: 10.1016/j.joca.2013.10.018. Epub 2013 Nov 8. Karsdal MA1, Christiansen C2, Ladel C3, Henriksen K2, Kraus VB4, Bay-Jensen AC2. Author information 1Nordic Bioscience, Herlev Hovedgade, DK-2730 Herlev, Denmark. Electronic address: mk@nordicbioscience.com. 2Nordic Bioscience, Herlev Hovedgade, DK-2730 Herlev, Denmark. 3Merck-Serono Research, Merck KGaA, Darmstadt, Germany. 4Division of Rheumatology, Department of Medicine, Duke University(…)

Predictive factors of response to biological disease modifying antirheumatic drugs: towards personalized medicine.

Daïen CI1, Morel J1. Author information Abstract Many therapies are now available for patients with rheumatoid arthritis (RA) who have an inadequate response to methotrexate including tumor necrosis factor inhibitors, abatacept, tocilizumab, and rituximab. Clinical response to drugs varies widely between individuals. A part of this variability is due to the characteristics of the patient(…)